EPID-01. GLIOBLASTOMA TREATMENT OF BEVACIZUMAB ERA IN KANSAI REGION, JAPAN

Randomized trials failed to prove the efficacy of Bevacizumab on OS of newly diagnosed glioblastomas, but improvement of PFS was revealed. Based on these results, Japanese national health insurance approved Bevacizumab (Bev) for both primary and recurrent glioblastoma treatment in 2013. And at same...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Mori, Kanji, Shofuda, Tomoko, Okita, Yoshiko, Arita, Hideyuki, Kinoshita, Manabu, Terakawa, Yuzo, Tsuyuguchi, Naohiro, Tomogane, Yusuke, Fukai, Junya, Ishibashi, Kenichi, Nishida, Namiko, Taki, Takuyu, Nonaka, Masahiro, Izumoto, Shuichi, Moriuchi, Shusuke, Nakajima, Yoshikazu, Hashimoto, Naoya, Kodama, Yoshinori, Hirose, Takanori, Kanemura, Yonehiro
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693178/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.279
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars